General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises P3 Health Partners in Completed Business Combination With Foresight Acquisition Corp.

December 6, 2021
A corporate deal team advised the health management company on the de-SPAC transaction to become publicly traded.

P3 Health Partners, a patient-centered and physician-led population health management company, has announced that it has closed its previously announced business combination with Foresight Acquisition Corp. (Nasdaq: FORE) (Foresight). The transaction was approved at a special meeting of Foresight’s stockholders on December 3, 2021. The combined company will be named P3 Health Partners Inc. and will be led by P3’s management team. Its shares of Class A common stock and warrants are expected to begin trading December 6, 2021, on the Nasdaq under the ticker symbols “PIII” and “PIIIW”, respectively.

Latham & Watkins LLP represents P3 Health Partners in the transaction with a corporate deal team led by Orange County/New York partner Charles Ruck, Orange County partner Scott Shean and Boston partners Wesley Holmes and Elisabeth Martin, with associates Christopher Martinez, Nuri Ruzi, Peter Bassine, and Caitlin Nguyen. Advice was also provided on tax matters by Washington, D.C. partner Andrea Ramezan-Jackson, with associate Emmanuel Kassim, and on benefits and compensation matters by Los Angeles partner Michelle Carpenter and Los Angeles counsel Aryeh Zuber, with Los Angeles associate Tara McCarney.